Introduction: In the realm of modern therapeutics, peptides have emerged as a powerful and versatile class of molecules, unlocking their potential through continuous advancements in innovative technologies. Among these breakthroughs is mRNA display, a technique that has accelerated peptide discovery. This article explores the principles and key steps of mRNA display, as well as its …Read More >

Peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages, including high specificity, potent activity, and relatively low toxicity. These attributes make peptides highly attractive for targeting complex diseases, including cancer, metabolic disorders, and autoimmune conditions. As the demand for innovative peptide drugs continues to grow, the need …Read More >

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a serious liver disease. If left untreated, MASH can lead to cirrhosis, liver failure, and liver cancer. The main characteristics of MASH include fat accumulation, inflammation, fibrosis, and hepatocyte ballooning in the liver. The pathogenesis of MASH is complex and involves multiple interacting factors, …Read More >

Introduction: OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as well as our recent progress in preclinical research. In this issue, we showcase non-human primate pain animal models. https://onco.wuxiapptec.com Pain is defined as an unpleasant sensory and emotional experience associated or similar to actual or …Read More >

Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency of cytotoxic drugs.  This type of targeted delivery can minimize harm to healthy tissues, reducing side effects and potentially improving the therapeutic window. However, the complex structure of ADCs poses significant development and safety challenges …Read More >

Diabetic neuropathy, a common complication of diabetes, affects approximately 50% of diabetic patients and can lead to a range of symptoms, including chronic pain, numbness, and loss of sensation in the extremities, particularly the feet. Animal models are crucial for understanding the mechanisms of diabetic neuropathy and developing novel treatments. However, reproducing the complexity of …Read More >

Diabetic retinopathy is a major contributor to vision loss and blindness in working-age adults with diabetes. Developing animal models that accurately represent human diabetic retinopathy is challenging because this disease is complex and involves multiple factors, including genetic predisposition, duration of diabetes, and glycemic control. It is crucial to replicate the human pathophysiology in these …Read More >

Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a promising therapeutic approach in the treatment of various cancers, particularly those with deficiencies in DNA repair mechanisms. However, the clinical efficacy of PARPi is often limited by the development of resistance, which poses a significant challenge to their long-term use. Elucidating the molecular mechanisms underlying PARPi …Read More >

Advances in understanding how the body regulates metabolism, particularly the role of incretin hormones, have directly led to the development of effective therapies for improving glycemic control and managing weight, particularly for individuals with type 2 diabetes and/or obesity. These medications, such as GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, mimic or enhance the …Read More >